CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AtaiBeckley Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AtaiBeckley Inc
NEW YORK, NY  10119  United States Ticker: ATAIATAI
This company ceased filing statements with the SEC on 12/31/2025.
Business Summary
AtaiBeckley Inc is a clinical-stage biotechnology company focused on developing rapid-acting, durable and convenient mental health treatments. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Supervisory Board ChristianAngermayer 46 1/1/2021 1/1/2021
Chief Executive Officer, Co-Founder, Interim Managing Director SrinivasRao 56 1/1/2025 4/1/2019
Chief Financial Officer Michael E.Faerm 59 3/9/2026 3/9/2026
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
ATAI LIFE SCIENCES UK LTD ONE FLEET PLACE LONDON United Kingdom
Beckley Psytech Limited Beckley Park Oxford United Kingdom
Atai Life Sciences 200 Berkeley Street Boston MA United States

Business Names
Business Name
ATAI
ATAI LIFE SCIENCES
Beckley Psytech Limited
4 additional Business Names available in full report.

General Information
Number of Employees: 99 (As of 12/31/2025)
Outstanding Shares: 364,745,985 (As of 2/27/2026)
Shareholders: 344
Stock Exchange: NASD
Federal Tax Id: 413357923
Fax Number: (302) 655-5049


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, March 24, 2026